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Background: Low protein expression of E-cadherin in oral squamous cell carcinoma (OSCC) has been associated 
with clinical and histopathological traits such as metastases, recurrence, low survival and poor tumor differentia-
tion, and it is considered a high-risk marker of malignancy. However, it is still unknown whether low expression 
of E-cadherin is also present at the mRNA level in OSCC cases. Objective: The aim of this study was to compare 
E-cadherin mRNA expression in OSCC patients and controls and to correlate the expression with clinical and 
prospective characteristics. 
Material and Methods: Forty patients and 40 controls were enrolled. E-cadherin mRNA expression was evaluated 
by quantitative real-time polymerase chain reaction using TaqMan probes. 
Results: E-cadherin mRNA expression was significantly decreased in OSCC patients compared to that of controls 
(p<0.001). Whereas no significant association between clinical parameters and E-cadherin expression levels was 
observed, we noted lower E-cadherin expression levels in patients with positive lymph node metastasis. 
Conclusions: E-cadherin mRNA expression was markedly diminished in OSCC, in agreement with previous re-
sults that examined E-cadherin expression at the protein level. E-cadherin is downregulated in the early clinical 
stages of OSCC, and its mRNA levels do not change significantly in the advanced stages, suggesting that there is 
limited usefulness of this parameter for predicting disease progression.
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Introduction
Global demographic transitions suggest that there will 
be an increase in cancer burden over the next several 
decades, particularly in middle- and low-income coun-
tries (1). In 2012, GLOBOCAN reported that oral cancer 
made up approximately 2.1% of newly registered cancer 
cases. According to this study, approximately 145,000 
deaths occurred because of oral cancer 77% of which 
occurred in less developed regions (2).
Oral squamous cell carcinoma (OSCC) is the most com-
mon histological cancer type of the oral cavity (3), and 
it is considered to have a multifactorial etiology due to 
the synergy of multiple risk factors (4,5).
In the advanced stages, neoplastic cells undergo a dedif-
ferentiation process, which is followed by a loss of in-
tercellular adherence. Intercellular adhesion is primarily 
maintained by cadherin adhesion molecules, and specifi-
cally by E-cadherin in the epithelial tissue (6). E-cad-
herin is a 120 kDa transmembrane glycoprotein encoded 
by the CDH1/E-cadherin gene located on chromosome 
16q22.1, and it is considered a tumor suppressor gene due 
to its ability to negatively regulate cell proliferation (7). 
E-cadherin downregulation normally occurs during em-
bryogenesis in the context of an epithelial-mesenchymal 
transition (EMT) (8-10), which allows cells to migrate to 
other embryonic layers. Similarly, neoplastic cells mi-
grate and reach distant organs in malignant tumors of 
epithelial origin after undergoing an EMT that involves 
decreased E-cadherin expression (8).
Accordingly, low expression of E-cadherin in OSCC 
has been associated with clinical and histopathological 
features of malignancy, such as metastasis, recurrence, 
low survival and poor tumor differentiation (11-13), 
and it has been referred to by some authors as a “high-
risk marker of malignancy” (14,15). However, in most 
studies, E-cadherin expression has been assessed at the 
protein level using immunohistochemistry (12,15-23). 
Cancer is a genomic disease (24), and gene expression 
at the mRNA level of markers involved in carcinogen-
esis, such as E-cadherin, needs to be evaluated in OSCC 
in the context of clinical characteristics associated with 
the disease. The aim of this study was to quantify the 
gene expression levels of E-cadherin in oral cancer pa-
tients and controls and to evaluate their association with 
tumor, node, metastasis (TNM) stage, persistence, re-
currence, death, and response to therapy.
Material and Methods
A total of 40 cases of primary OSCC were diagnosed 
over a period of 3 years (2012-2015) (24 males and 16 fe-
males, aged 60.8 ± 15.7 years) at the Instituto Jaliscience 
de Cancerología (Jaliscience Cancer Institute); no anti-
cancer therapy had been initiated in any of these cases. 
The 40 control samples were obtained from patients (22 
male and 18 female subjects aged 58.7 ± 17.5 years) who 
visited the maxillofacial surgery service at the Hospital 
Civil Nuevo (New Civil Hospital) for tooth extraction 
with prosthetic and orthodontic indications. For each 
patient, data regarding the following clinico-patholog-
ical factors were collected: gender, age, smoker status, 
alcohol consumption, TNM stage, recurrence, persis-
tence and date of death. The exclusion criteria for both 
groups were having or having had any type of cancer 
other than OSCC, being diagnosed with an autoimmune 
disease that affected the oral cavity, such as pemphigus 
vulgaris or lichen planus, or not signing the informed 
consent. Protocol was reviewed and accepted by Uni-
versidad de Guadalajara biosecurity and etic committee 
number CI-02112
-Clinical and prospective data
The stage of the disease was evaluated at the Surgical Head 
and Neck Oncology Department of the Jaliscience Cancer 
Institute, and each tumor was analyzed clinically and by 
computerized tomography. The disease stages were then 
determined according to the TNM system (AJCC) (25).
Due to the finding that the diameter of the tumor and in-
vasion into lymphatic nodes are regarded as important 
clinical markers involved in prognosis, the lymphatic 
nodes were considered positive if patients presented 
with metastasis in one or more lymphatic nodes. T stage 
and total TNM scores were assigned in accordance with 
the National Cancer Institute guidelines, and each case 
was determined to be early- or advanced-stage disease 
(NCI, 2016) (26). According to this system, advanced T 
stage refers to tumors that are larger than 4 cm, where-
as advanced TNM stage also incorporates tumors of a 
smaller size that are accompanied by positive lymphatic 
nodes with or without distant metastasis.
Prospective data were taken and updated each year after 
diagnosis and at the beginning of anticancer treatment. 
The average follow-up was 43.02 ± 13.48 months, with 
a minimum of 21 months and a maximum of 65 months. 
Persistence was diagnosed in patients who showed tu-
moral activity based on imaging studies after a 9 to 12 
month period after the conclusion of therapy, according 
to the criteria previously described by DeSouza et al. 
(27). Additionally, recurrence of the disease was defined 
as, despite there being a period of time with eradication 
of clinical and imaging manifestations of disease, also 
known as disease-free period or disease-free interval, 
the reappearance of cancer, whether in the location of 
the original tumor (local recurrence), in regional lymph 
nodes or in adjacent tissues (regional recurrence), or if 
it had disseminated to any other body part (distant re-
currence) (28). A patient was considered to be a non-
responder to anticancer therapy if they experienced re-
currence and/or persistence.
-Sample retrieval and storage
A fresh tissue sample that was at least 5 mm in diam-
eter was obtained at the time of the surgical procedure, 
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during biopsy in the OSCC group and tooth extraction 
in the control group. Samples were stored in a -80°C 
freezer.
-RNA isolation and cDNA synthesis
RNA extraction from tissue samples was performed 
using TRIzol (Invitrogen®) reagent coupled with Poly-
tron® (Kinematica Inc.) homogenization at room tem-
perature (RT). Afterwards, 200 µl of chloroform was 
added for every 750 µl of TRIZOL. Samples were shak-
en vigorously using a vortex for 15 seconds, incubated 
at room temperature for 5 minutes, and centrifuged 
at 11000 rpm for 10 minutes at 4°C. The upper aque-
ous phase was transferred carefully to precipitate the 
RNA by mixing with 1 volume of isopropanol. Samples 
were incubated at RT for 15 minutes and centrifuged at 
14000 rpm for 10 minutes at 4°C. Next, samples were 
washed with 80% ethanol in diethyl pyrocarbonate wa-
ter, and the RNA pellet was air-dried for 5-10 minutes. 
RNA concentration and quality were measured using 
a NanoDrop Spectrophotometer (NanoDrop Technolo-
gies, Wilmington, DE). cDNA was synthesized from 
100 ng of total RNA using a High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems) according 
to the manufacturer’s instructions. cDNA samples were 
stored at −20°C.
-Relative quantification by Real-Time Polymerase 
Chain Reaction (qRT-PCR)
Before quantification of the gene of interest, selection of 
an endogenous gene for normalization was performed 
by construction of standard curves. In this stage, a total 
of 100 ng cDNA was taken from 6 OSCC cases and 6 
controls to verify that the endogenous gene had no vari-
ation between study groups. Five serial dilutions of each 
cDNA were made to generate a concentration range 
from 25 ng to 200 ng. The qRT-PCR reactions to evalu-
ate the 18S RNAr, B2M, GAPDH and HPRT1 endog-
enous genes were performed in a final volume of 10 µL, 
1X TaqMan Universal PCR Master mix, 1X TaqMan 
Gene Expression Assay primer and probe mix (Applied 
Biosystems). The qPCR reactions were performed on a 
StepOne Plus Real-Time PCR System (Applied Biosys-
tems, Foster City, CA) according to the manufacturer ś 
instructions. Standard curves were compared using 
Student’s t-test. The gene 18S RNAr was selected be-
cause it had the lowest significance.
The relative mRNA expression levels of E-cadherin 
were determined using a TaqMan® Gene Expression 
Assay (Hs01023894_m1; Applied Biosystems). The 
TaqMan probe corresponded to the cdh1/E-cadherin 
gene joining at exons 2 and 3 from the 284 bp position 
and amplified a fragment of 61 bp. During the quanti-
fication of E-cadherin gene expression using the qRT-
PCR assay, 20 ng of cDNA from each patient sample 
was used in duplicate for each PCR (according to the 
mixing conditions previously described). The Cq values 
were normalized to those of the 18S-rRNA endogenous 
gene, and gene expression was calculated as the fold-
change relative to the average expression of the controls 
using the 2-ΔΔCt method.
-Immunohistochemistry (IHC)
To confirm the protein presence in the tumoral tissue, 
immunohistochemical technique was performed. . Tis-
sue samples were processed and evaluated. Three-μm-
thick sections were cut, placed on poly-L-lysine-coat-
ed slides, deparaffinized in a 60°C oven for 30 minutes 
and incubated in xylol for 5 minutes. The sections 
were then rehydrated in decreasing alcohol concentra-
tions (absolute, 90%, 70%, and 50%) and washed in 
distilled water. To retrieve the epitopes, the tissue sec-
tions were incubated in 10 mM sodium citrate solution, 
pH 9, in a microwave oven at a maximum power of 
750 W for two cycles of 5 minutes each. The sections 
were then cooled to room temperature and washed 
with distilled water. The endogenous peroxidases 
were blocked with 0.9% hydrogen peroxide, and the 
samples were washed again with distilled water and 
phosphate-buffered saline solution (PBS, pH 7.4). The 
sections were incubated for 30 minutes with primary 
antibodies against E-cadherin (Clone NCH-38, 1:50, 
Dako Corp., Carpinteria, CA, USA). Next, the sec-
tions were incubated with a biotinylated anti-mouse/
anti-rabbit secondary antibody and a streptavidin/per-
oxidase complex (LSAB+-labeled streptavidin-biotin, 
Dako Corp.) for 30 minutes each, and the reaction 
products were detected with 3,3′-diaminobenzidine-
H2O2 (Dako Corp.).
For microarray analysis, negative and positive controls 
were obtained from paraffin blocks containing samples 
of healthy mucosa and fibroma using a 5-mm punch and 
were placed on slides along with the samples.
The immunopositivity and immunolocalization were 
analyzed by an oral pathologist. The E-cadherin mem-
branal protein (mP) was expressed on the cell mem-
brane in all tumor tissues, regardless of the high or low 
expression status.
-Statistical Analysis
Comparisons were made between OSCC cases and 
controls by Student’s t-test. To perform Chi-square or 
Fisher’s exact test, the conversion of categorical vari-
ables was necessary; zero was considered to be the 
cutoff point for under- or overexpression. Comparisons 
between mRNA E-cadherin expression levels, mP E-
cadherin and disease characteristics, such as TNM and 
TNM clinical stage, and prospective data were calculat-
ed by the Mann-Whitney U-test and Chi square. Statis-
tical analysis was performed using SPSS statistics v23 
software, and ≤ 0.05 was considered to be statistically 
significant.
Results
Sociodemographic and risk factor profiles from the 
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OSCC case and control groups were obtained. Both 
groups were similar in regard to gender and age dis-
tribution as well as smoking status, whereas alcohol 
consumption was higher in the control group.  With the 
purpose of assessing the influence of risk factors on E-
cadherin gene expression, a comparative analysis be-
tween E-cadherin mRNA levels and alcohol or tobacco 
consumption was made in both case and control groups, 
without showing significant differences (t-student test, 
p-values are shown in Table 1).
The description of the clinical characteristics and pro-
spective data of patients with oral cancer showed that a 
majority of the patients presented tumors larger than 4 
cm, with regional lymph node metastasis and advanced 
TNM clinical stage (Table 2). However, none of the pa-
tients showed dissemination to distant organs. From the 
prospective data, it should be highlighted that most of 
the patients responded to the therapy and were still alive 
at the time that this paper was completed.
The difference in gene expression of E-cadherin be-
tween OSCC cases (-4.3 ± 5.6) and controls (-0.3 ± 
4.7) was significant (p< 0.001) (Fig. 1A), showing that 
E-cadherin was downregulated at the mRNA level in 
OSCC. Neither tumor size, lymph node status nor TNM 
stage showed a significant correlation with the E-cad-
herin mRNA level (Fig. 1B,C,D). However, we noted 
that patients with negative lymph node metastasis had a 
higher level of E-cadherin mRNA than that of patients 
with positive lymph node metastasis (-1.8 ± 5.6 vs -5.6 
± 5.3, respectively). Spearman’s rho was calculated with 
the aim of correlating the levels of mRNA E-cadherin 
with clinical parameters. Although the correlation was 




 Case  Control  
 Mean SD  Mean SD  
Age 60.8 15.7  58.7 17.5  
 No. %  No. %  
 Gender    
Female 17 42.5  24 60  
Male 23 57.5  16 40  
 Smoker       p value            p value  
No 19 47.5 .05* 21 52.5 .22* 
Yes 21 52.5  19 47.5  
  Alcohol  
No 19 47.5      .07* 33 82.5 .99* 
Yes 21 52.5  7 17.5  
Table 1: Sociodemographic, risk factor descriptive data and expression mRNA  E-cadherin difference from OSCC 
patients and the control group.
Abbreviation: OSCC, oral squamous cell carcinoma SD: Standard desviation. *T-student I.C. 95%.
indicated a positive weak correlation for tumor size (p 
= .003 rho = .332) and invasion of lymph nodes (p = 
.019 rho = .268) but, strikingky, the correlation becomes 
weakly negative for the global clinical stage (p = .001 
rho = -.389), where the trend line shows that as the clini-
cal stage increases, the mRNA levels decrease.
Prospective data (recurrence, persistence, response to 
therapy and death) were also not significantly related to 
E-cadherin mRNA levels (Fig. 2A-D), although there 
was a trend for lower values of E-cadherin expression 
in deceased (-6.8 ± 7.1) vs. living patients (-3.79 ± 5.36). 
The quantitative expression of E-cadherin was dichoto-
mized in high and low expression groups using a value 
of 0 as the cutoff and was used to generate survival anal-
ysis curves. The average survival in the high expression 
group was 48.7 ± 3.3 months, and survival was reduced 
to 44.8 ± 3.3 months in the low expression group, al-
though this difference was not significant. However, it 
can be seen in the survival curves that deaths occurred 
earlier in patients with low expression of E-cadherin 
(Fig. 2E).
E-cadherin at the cell membrane (mP E-cadherin) was 
marked by immunohistochemistry (Fig. 3A,B). Using 
Mann Whitney U test, a statistically significant relation 
between mP E-cadherin and E-cadherin mRNA levels 
in OSCC patients was observed (p=.03),  as tissues with 
low mP E-cadherin expression mostly had low levels 
of E-cadherin mRNA, and conversely tissues with high 
mP E-cadherin expressed high levels of E-cadherin 
mRNA (Fig. 3C). As expected, therefore, similarly to 
E-cadherin mRNA levels, using the Chi-square test we 
found that mP E-cadherin was not significantly associ-
ated with the clinical and prospective parameters T (p= 





 No. %  No. % 
T stage  Persistence  
 Advanced 25 62.5  Yes 11 27.5 
 Not advanced 15 37.5  No 29 72.5 
Lymph node metastasis  Recurrence  
 Positive 27 67.5  Yes 14 35.0 
 Negative 13 32.5  No 26 65.0 
TNM stage  Death  
 Advanced TNM stage 26 77.5  Yes 8 20.0 
 Early TNM stage 14 22.5  No 32 80.0 
    Therapy response   
     Yes 27 67.5 
     No 13 32.5 
 
	
Table 2: Clinical and prospective data from 40 OSCC patients.
Abbreviations: OSCC, oral squamous cell carcinoma. Tumor advanced, Lymph node metastasis and clinical TNM stages were assigned 
in accordance with the guidelines of the NCI.
Fig. 1: Student’s t-test. A) Comparison of the E-cadherin gene expression values between the OSCC case (mean -4.32 ± 5.67; minimum 
-15.46; maximum 6.38) and control (mean -.31 ± 4.72; minimum -13.32; maximum 6.70) groups. Mann–Whitney test. Comparison of the 
E-cadherin gene expression values in the T, N and TNM clinical stages. B) Tumor not advanced (< 4 cm) vs Tumor advanced (> 4 cm): 
mean 4.76 ± 5.81 vs -4.20 ± 5.93, minimum -10.19 vs -15.46, maximum 6.38 vs 5.40, respectively. C) Lymph node metastasis negative 
vs positive, mean -1.81 ± 5.67 vs -5.67 ± 5.37, minimum -9.96 vs -15.46, maximum 6.38 vs 3.83, respectively. D) TNM clinical stage not 
advanced vs advanced: mean -2.34 ± 7.04 vs -4.43 ± 5.49, minimum -9.96 vs -15.46, maximum 6.38 vs 5.40, respectively.
.67), N (p= .12), TNM clinical stage (p= .26) and recur-
rence (p= .86), persistence (p= .85), therapy response 
(p= .48) and death (p= .52).  
Discussion
E-cadherin downregulation at the mRNA level occurs 
due to several mechanisms and plays a key role in the 
cell motility that is required for the invasion and metas-
tasis cancer hallmark to occur (29).
Despite the crucial role of E-cadherin downregulation 
in cancer, only two previous studies, to our knowledge, 
have analyzed the mRNA expression of E-cadherin in 
OSCC tumors. Wang et al. found that the expression 
of E-cadherin mRNA in the invasive tumor front was 
lower than in the central region (18). Their study did not 
report a comparison of the mRNA expression of E-cad-
herin with the clinical and prospective data of oral can-
cer patients. Yao et al. (23) analyzed the mRNA levels 
of E-cadherin by qRT-PCR using the 2- ΔΔCt method 
in 20 samples of oral cancer, but they used normal tis-
sue adjacent to the tumor as the control group. In their 
study, they reported significant differences between tu-
moral tissue and adjacent normal tissue, but they did not 
report associations between E-cadherin mRNA expres-
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Fig. 2: Comparison of the E-cadherin gene expression values and prospective data. A) Recurrence, no vs yes: mean -1.81 ± 5.32 vs -4.05 ± 
6.38, minimum -13.00 vs -12.00, maximum 6.7 vs 5.4, respectively. B) Persistence, no vs yes: mean -4.19 ±5.30 vs -4.16 ± 7.16, minimum 
-13.95 vs -12.00, maximum 6.38 vs 5.40. C) Therapy response, no vs yes: mean -4.49 ± 6.53 vs -3.60 ± 5.15, minimum -12.00 vs -13.95, maxi-
mum 5.40 vs 6.38, respectively. D) Death, no vs yes: mean -3.79 ± 5.36 vs -6.80 ± 7.18, minimum -15.46 vs -13.95, maximum 6.38 vs 3.83, 
respectively. E) Kaplan–Meier survival curve for overall survival according to high/low E-cadherin mRNA expression and survival time. 
Survival with low E-cadherin mRNA expression (orange line) decreases earlier than with high E-cadherin mRNA expression (blue line).
Fig. 3: All tumors showed membranal protein (mP) E-cadherin expression at different intensities A) High mP expression of 
E-cadherin by immunohistochemistry in well-differentiated OSCC B) Low mP expression of E-cadherin by IHC in OSCC (mag-
nification 40x). Mann-Whitney tests. C) Tissue with low mP E-cadherin: mean of -5.48 ± 4.8, minimum  -12.00, maximum .92. 
Tissue with high mP E-cadherin: mean .39 ± 5.47,  minimum -10.19, maximum 6.38. 
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sion and clinical parameters of OSCC. 
Our study is, to the best of our knowledge, the first to 
analyze the expression of E-cadherin mRNA in tumors 
from patients with OSCC and in a real control group, as 
well as the first study to correlate E-cadherin mRNA 
levels with clinical and prospective characteristics of 
the disease. We consider that the most reliable control 
tissue is one that comes from a completely healthy 
area from an individual without OSCC, instead of tis-
sue from an area adjacent to the tumor, which can be 
exposed to the same microenvironment as the tumor 
itself. The tumor microenviroment plays key roles dur-
ing the initiation of the carcinogenesis process (29), and 
therefore normal-looking tissue adjacent to the tumor 
may carry some of the alterations in genes and signal-
ling networks operating in the neighboring cancer cells, 
making such tissues an unreliable control.
In this study, E-cadherin mRNA expression was mark-
edly diminished in OSCC tumors, in agreement with 
previous data on E-cadherin protein levels (11-13). 
However, low E-cadherin expression at the mRNA level 
occurred in the early clinical stages and did not con-
tinue to decrease significantly in the advanced stages, 
so its potential usefulness for OSCC staging seems lim-
ited. Nevertheless, we observed a trend towards further 
decreases in E-cadherin mRNA levels with positive 
lymph node metastasis and a weak negative correlation 
with TNM clinical stage. 
One limitation of this type of studies is, on the one hand 
that E-cadherin gene expression, although constitutive, 
can be regulated by causes other than the carcinogenesis 
process, such as wound repair, inflammatory processes 
and immune response. On the other hand, there might 
be variations in the proportion of epithelial or mesen-
chymal tissue present in the tissue extracted from each 
sample, as well as variations in the precise tumor area 
from which the sample is obtained (front of tumoral ad-
vance or central tumor area), which constitutes another 
possible limitation of these studies.
Future studies with larger sample sizes will be needed 
to ascertain whether the E-cadherin mRNA level could 
eventually constitute a predictor of lymph node me-
tastasis in OSCC. Such studies would also allow us to 
confirm our results regarding the non-significant cor-
relations of E-cadherin mRNA levels with prospective 
variables such as persistence, recurrence and therapy 
response.
E-cadherin is regulated by several transcriptional fac-
tors that have emerged as important transcriptional re-
pressors of E-cadherin during EMT in gastrulation, in 
addition to having specific roles in the tumorigenicity 
and metastatic behavior of squamous cell carcinomas 
in vitro. These E-cadherin regulatory mechanisms in-
clude the SNAIL superfamily (Snail 1 and Snail 2) (30), 
SIP1 (31), the microRNA family that includes miR200 
and miR-2056,(32), proteins produced by the human 
papilloma virus type 16, E6 and E7 (the reduction of 
E-cadherin on the cell surface in the presence of these 
proteins has been shown in vitro) (33-35), as well as the 
coexpression of ErbB-2 (36).
Likewise, gene expression is also regulated epigeneti-
cally, regulating gene expression through changes in the 
structure of chromatin that results from the transfer of 
methyl groups.
Several authors have chosen to study concomitantly the 
expression of E-cadherin with some of the regulatory 
proteins in situ (22,37); thus, it would be interesting for 
future studies to include an evaluation of various tran-
scriptional or regulatory factors and the epigenetics in-
volved in the expression of E-cadherin specifically in 
oral squamous cell carcinomas.
In conclusion, our study confirms the importance of 
gene expression E-cadherin levels in OSCC and shows 
that its downregulation at the mRNA level is likely to 
be an early and constant event in the evolution of this 
disease. Further studies will be necessary to establish 
whether E-cadherin levels continue to decrease signifi-
cantly as OSCC progresses.
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